NASDAQ:MTEM Molecular Templates (MTEM) Stock Forecast, Price & News $6.52 +0.29 (+4.65%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$6.30▼$6.6050-Day Range$6.12▼$9.3052-Week Range$4.65▼$12.53Volume11,270 shsAverage Volume11,206 shsMarket Capitalization$35.08 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Molecular Templates MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.1% Upside$15.00 Price TargetShort InterestBearish1.43% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.65Based on 3 Articles This WeekInsider TradingAcquiring Shares$2 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($6.15) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector329th out of 966 stocksPharmaceutical Preparations Industry127th out of 438 stocks 3.5 Analyst's Opinion Consensus RatingMolecular Templates has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Molecular Templates has a forecasted upside of 130.1% from its current price of $6.52.Amount of Analyst CoverageMolecular Templates has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.43% of the float of Molecular Templates has been sold short.Short Interest Ratio / Days to CoverMolecular Templates has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Molecular Templates has recently increased by 9.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMolecular Templates does not currently pay a dividend.Dividend GrowthMolecular Templates does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMolecular Templates has received a 72.55% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Molecular Templates is -0.93. Previous Next 2.0 News and Social Media Coverage News SentimentMolecular Templates has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Molecular Templates this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Molecular Templates to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Molecular Templates insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,999,993.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.40% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Molecular Templates are expected to grow in the coming year, from ($6.15) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Templates is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Templates is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Molecular Templates (NASDAQ:MTEM) StockMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Read More MTEM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTEM Stock News HeadlinesSeptember 30, 2023 | seekingalpha.comMolecular Templates appoints Maurizio Voi as chief medical officerSeptember 30, 2023 | finanznachrichten.deMolecular Templates, Inc.: Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical OfficerOctober 4, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 28, 2023 | finance.yahoo.comMolecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical OfficerAugust 31, 2023 | msn.comMolecular Templates (MTEM) Price Target Increased by 1400.00% to 38.25August 11, 2023 | finanznachrichten.deMolecular Templates, Inc.: Molecular Templates Announces 1-for-15 Reverse Stock SplitAugust 11, 2023 | finance.yahoo.comMolecular Templates Announces 1-for-15 Reverse Stock SplitAugust 10, 2023 | msn.comMolecular Templates GAAP EPS of -$0.19 beats by $0.15, revenue of $6.87M beats by $4.29MOctober 4, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 10, 2023 | finance.yahoo.comMolecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business UpdateAugust 4, 2023 | finance.yahoo.comAfter layoffs, Molecular Templates overhauls C-suiteJuly 13, 2023 | seekingalpha.comMolecular Templates launches $40M private placementJuly 6, 2023 | msn.comMolecular Templates (MTEM) Price Target Decreased by 76.19% to 2.55June 1, 2023 | finance.yahoo.comMolecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary MyelomaApril 17, 2023 | finance.yahoo.comImproved Revenues Required Before Molecular Templates, Inc. (NASDAQ:MTEM) Stock's 45% Jump Looks JustifiedApril 11, 2023 | finanznachrichten.deMolecular Templates, Inc.: Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169April 7, 2023 | finance.yahoo.comMolecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169March 30, 2023 | finance.yahoo.comMolecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business UpdateMarch 10, 2023 | investorplace.comWhy Is Molecular Templates (MTEM) Stock Up 36% Today?March 9, 2023 | marketwatch.comMolecular Templates Shares Rise 18% After FDA Accepts MT-8421 New Drug AppJanuary 25, 2023 | dailymail.co.ukNASA's James Webb spots 'building blocks of life': Elements of habitable worlds found in the darkest, coldest molecular cloud ever seen in spaceJanuary 14, 2023 | finance.yahoo.comGlobal Molecular Spectroscopy Market to Surpass US$ 3,835.1 Million by 2030, Says Coherent Market Insights (CMI)December 22, 2022 | benzinga.comLooking Into Molecular Templates's Return On Capital EmployedDecember 3, 2022 | finance.yahoo.comMolecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual MeetingNovember 24, 2022 | finance.yahoo.comMolecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare ConferenceNovember 10, 2022 | finance.yahoo.comMolecular Templates, Inc. Reports Third Quarter 2022 Financial ResultsAugust 31, 2022 | finance.yahoo.comMolecular Templates Announces Participation in Four Upcoming ConferencesSee More Headlines Receive MTEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter. Email Address MTEM Company Calendar Last Earnings8/10/2023Today10/03/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MTEM CUSIP88580720 CIK1183765 Webwww.mtem.com Phone(512) 869-1555Fax650-474-2529Employees111Year Founded2009Price Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+130.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($12.4438) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,720,000.00 Net Margins-92.78% Pretax Margin-92.68% Return on Equity-1,843.37% Return on Assets-58.76% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual Sales$19.75 million Price / Sales1.78 Cash FlowN/A Price / Cash FlowN/A Book Value($4.03) per share Price / Book-1.62Miscellaneous Outstanding Shares5,380,000Free Float4,656,000Market Cap$35.08 million OptionableNot Optionable Beta1.45 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Eric E. Poma Ph.D. (Age 51)CEO, Chief Scientific Officer & Director Comp: $923.34kMs. Jason S Kim (Age 48)Pres, CFO, Treasurer & Principal Accounting Officer Comp: $639.85kDr. Gabriela Gruia M.D. (Age 67)Interim Chief Medical Officer & Director Comp: $33kMs. Kristen Quigley B.A. (Age 52)Chief Operating Officer Dr. Grace KimChief Strategy Officer & Head of IRDr. Joseph Phillips Ph.D.Sr. VP & Head of CMC Devel.Ms. Megan C. FiloonSec.More ExecutivesKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTFortress BiotechNASDAQ:FBIORegulus TherapeuticsNASDAQ:RGLSCatalyst BiosciencesNASDAQ:CBIOAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInsiders & InstitutionsBlackRock Inc.Sold 151,121 shares on 8/11/2023Ownership: 1.060%Acadian Asset Management LLCSold 70,412 shares on 8/7/2023Ownership: 0.291%Target N V BiotechBought 283,687 shares on 7/17/2023Total: $2.00 M ($7.05/share)View All Insider TransactionsView All Institutional Transactions MTEM Stock - Frequently Asked Questions Should I buy or sell Molecular Templates stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MTEM shares. View MTEM analyst ratings or view top-rated stocks. What is Molecular Templates' stock price forecast for 2023? 1 equities research analysts have issued 1 year target prices for Molecular Templates' shares. Their MTEM share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 130.1% from the stock's current price. View analysts price targets for MTEM or view top-rated stocks among Wall Street analysts. How have MTEM shares performed in 2023? Molecular Templates' stock was trading at $4.92 at the beginning of the year. Since then, MTEM stock has increased by 32.5% and is now trading at $6.52. View the best growth stocks for 2023 here. When is Molecular Templates' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our MTEM earnings forecast. How were Molecular Templates' earnings last quarter? Molecular Templates, Inc. (NASDAQ:MTEM) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($3.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.25) by $1.95. The biotechnology company earned $6.87 million during the quarter. Molecular Templates had a negative net margin of 92.78% and a negative trailing twelve-month return on equity of 1,843.37%. When did Molecular Templates' stock split? Molecular Templates's stock reverse split on the morning of Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Molecular Templates own? Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL). What is Molecular Templates' stock symbol? Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM." How do I buy shares of Molecular Templates? Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Molecular Templates' stock price today? One share of MTEM stock can currently be purchased for approximately $6.52. How much money does Molecular Templates make? Molecular Templates (NASDAQ:MTEM) has a market capitalization of $35.08 million and generates $19.75 million in revenue each year. The biotechnology company earns $-92,720,000.00 in net income (profit) each year or ($12.4438) on an earnings per share basis. How many employees does Molecular Templates have? The company employs 111 workers across the globe. How can I contact Molecular Templates? Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529. This page (NASDAQ:MTEM) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.